302 related articles for article (PubMed ID: 33059055)
1. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis.
Zhuang L; Li J; Zhang Y; Ji S; Li Y; Zhao Y; Li B; Li W; Quan M; Duan Y; Zhao H; Cheng D; Wang X; Ou W; Xing H
Ann Hepatol; 2021; 23():100268. PubMed ID: 33059055
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS; Shahoumian TA; Loomis TP; Backus LI
J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
6. Treatment failure with DAA therapy: Importance of resistance.
Sarrazin C
J Hepatol; 2021 Jun; 74(6):1472-1482. PubMed ID: 33716089
[TBL] [Abstract][Full Text] [Related]
7. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Pearlman BL; Hinds AE
Aliment Pharmacol Ther; 2018 Nov; 48(9):914-923. PubMed ID: 30288771
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
[TBL] [Abstract][Full Text] [Related]
9. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
12. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
13. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
[TBL] [Abstract][Full Text] [Related]
16. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
[TBL] [Abstract][Full Text] [Related]
18. [Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Tergast TL; Kordecki N; Ohlendorf V; Beier C; Sandmann L; Wedemeyer H; Cornberg M; Maasoumy B
Z Gastroenterol; 2022 Jun; 60(6):959-962. PubMed ID: 34666403
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
[TBL] [Abstract][Full Text] [Related]
20. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
